IV PERSANTINE Drug Patent Profile
✉ Email this page to a colleague
When do Iv Persantine patents expire, and when can generic versions of Iv Persantine launch?
Iv Persantine is a drug marketed by Boehringer Ingelheim and is included in one NDA.
The generic ingredient in IV PERSANTINE is dipyridamole. There are eighteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the dipyridamole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Iv Persantine
A generic version of IV PERSANTINE was approved as dipyridamole by BARR on October 3rd, 1990.
Summary for IV PERSANTINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 148 |
| Clinical Trials: | 9 |
| Patent Applications: | 4,272 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | IV PERSANTINE at DailyMed |
Recent Clinical Trials for IV PERSANTINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Guo-Qing Jiang | N/A |
| Children's Hospital of Fudan University | Phase 1/Phase 2 |
| Shanghai Children's Hospital | Phase 1/Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for IV PERSANTINE
US Patents and Regulatory Information for IV PERSANTINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | IV PERSANTINE | dipyridamole | INJECTABLE;INJECTION | 019817-001 | Dec 13, 1990 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
